TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets
family transcription factors driving tumor progression. TK216 is designed to inhibit this
effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a
first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to
establish initial safety and efficacy data in monotherapy and in combination with vincristine
to assess the potential of TK216 for further development.